Christina E Nixon, Sangshin Park, Sunthorn Pond-Tor, Dipak Raj, Lynn E Lambert, Sachy Orr-Gonzalez, Emma K Barnafo, Kelly M Rausch, Jennifer F Friedman, Michal Fried, Patrick E Duffy, Jonathan D Kurtis
{"title":"新型疟疾候选疫苗恶性疟原虫分裂体输出抗原保护性b细胞表位的鉴定","authors":"Christina E Nixon, Sangshin Park, Sunthorn Pond-Tor, Dipak Raj, Lynn E Lambert, Sachy Orr-Gonzalez, Emma K Barnafo, Kelly M Rausch, Jennifer F Friedman, Michal Fried, Patrick E Duffy, Jonathan D Kurtis","doi":"10.1128/CVI.00068-17","DOIUrl":null,"url":null,"abstract":"<p><p>Naturally acquired antibodies to <i>Plasmodium falciparum</i> schizont egress antigen 1 (PfSEA-1A) are associated with protection against severe malaria in children. Vaccination of mice with SEA-1A from <i>Plasmodium berghei</i> (PbSEA-1A) decreases parasitemia and prolongs survival following <i>P. berghei</i> ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear B-cell epitopes using peptide microarrays probed with antisera from nonhuman primates vaccinated with recombinant PfSEA-1A (rPfSEA-1A). We evaluated the relationship between epitope-specific antibody levels and protection from parasitemia in a longitudinal treatment-reinfection cohort in western Kenya. Antibodies to three epitopes were associated with 16 to 17% decreased parasitemia over an 18-week high transmission season. We are currently designing immunogens to enhance antibody responses to these three epitopes.</p>","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":"24 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1128/CVI.00068-17","citationCount":"11","resultStr":"{\"title\":\"Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1.\",\"authors\":\"Christina E Nixon, Sangshin Park, Sunthorn Pond-Tor, Dipak Raj, Lynn E Lambert, Sachy Orr-Gonzalez, Emma K Barnafo, Kelly M Rausch, Jennifer F Friedman, Michal Fried, Patrick E Duffy, Jonathan D Kurtis\",\"doi\":\"10.1128/CVI.00068-17\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Naturally acquired antibodies to <i>Plasmodium falciparum</i> schizont egress antigen 1 (PfSEA-1A) are associated with protection against severe malaria in children. Vaccination of mice with SEA-1A from <i>Plasmodium berghei</i> (PbSEA-1A) decreases parasitemia and prolongs survival following <i>P. berghei</i> ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear B-cell epitopes using peptide microarrays probed with antisera from nonhuman primates vaccinated with recombinant PfSEA-1A (rPfSEA-1A). We evaluated the relationship between epitope-specific antibody levels and protection from parasitemia in a longitudinal treatment-reinfection cohort in western Kenya. Antibodies to three epitopes were associated with 16 to 17% decreased parasitemia over an 18-week high transmission season. We are currently designing immunogens to enhance antibody responses to these three epitopes.</p>\",\"PeriodicalId\":10271,\"journal\":{\"name\":\"Clinical and Vaccine Immunology\",\"volume\":\"24 7\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1128/CVI.00068-17\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Vaccine Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1128/CVI.00068-17\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/7/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/CVI.00068-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/7/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1.
Naturally acquired antibodies to Plasmodium falciparum schizont egress antigen 1 (PfSEA-1A) are associated with protection against severe malaria in children. Vaccination of mice with SEA-1A from Plasmodium berghei (PbSEA-1A) decreases parasitemia and prolongs survival following P. berghei ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear B-cell epitopes using peptide microarrays probed with antisera from nonhuman primates vaccinated with recombinant PfSEA-1A (rPfSEA-1A). We evaluated the relationship between epitope-specific antibody levels and protection from parasitemia in a longitudinal treatment-reinfection cohort in western Kenya. Antibodies to three epitopes were associated with 16 to 17% decreased parasitemia over an 18-week high transmission season. We are currently designing immunogens to enhance antibody responses to these three epitopes.
期刊介绍：
Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
